VERAXA Biotech (NASDAQ: VRXA), Secarna Partnership Milestone Opens New Potential Market for Conjugation Technology
VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, and Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of best-in-class oligonucleotide therapeutics, have reached an early research milestone in their collaboration to develop antibody oligonucleotide conjugates (“AOCs”), providing VERAXA with an initial proof point for applying its […]
Investor Brand Network
VERAXA Biotech (NASDAQ: VRXA) Advances VXA-222 Cancer Program Beyond Discovery Phase
VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has moved its VXA-222 bispecific antibody-drug conjugate program into the next stage of development after completing the initial phase of its collaboration with OmniAb, giving the biotechnology company a new development milestone while it continues expanding the intellectual-property estate underpinning its antibody technology […]
Investor Brand Network
VERAXA Biotech (NASDAQ: VRXA) Builds Antibody-Based Cancer Pipeline Around Dual-Targeting Precision
VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, is advancing its oncology pipeline with a strategy centered on changing how antibody-based therapies recognize and attack cancer cells. The biotechnology company is developing bispecific antibody-drug conjugates, T-cell engagers and other engineered antibody formats, with its proprietary BiTAC technology providing the distinctive element […]
Investor Brand Network
VERAXA Biotech (NASDAQ: VRXA) Advances VXA-222 Cancer Program While Expanding Patent Portfolio for Next-Generation Antibody Technologies
VERAXA (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has reached another development milestone in its oncology pipeline, announcing that its VXA-222 bispecific antibody-drug conjugate (“bsADC”) program has advanced beyond the discovery phase and into the next stage of development. The milestone reflects continued progress across the company’s therapeutic portfolio as it simultaneously […]
Investor Brand Network
VERAXA Biotech (NASDAQ: VRXA) Strengthens Scientific Leadership as New CSO Takes the Helm in Advancing BiTAC(R) Cancer Therapy Platform
VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has appointed antibody therapeutics researcher Christoph Erkel, Ph.D., as Chief Scientific Officer, reinforcing the company’s focus on advancing its proprietary BiTAC(R) technology platform as it prepares its lead oncology programs for clinical development. The announcement comes at a time when the biotechnology company […]
Investor Brand Network
VERAXA Biotech (NASDAQ: VRXA) Expands Patent Portfolio to Support Next-Generation Cancer Therapy Platforms
VERAXA Biotech (NASDAQ: VRXA) announced an expansion of its intellectual property portfolio, filing new patent applications during the first half of 2026 covering its next-generation BiTAC-TCE and BiTAC-ADC technology platforms and related therapeutic programs. The company said previously granted patents protecting supporting technologies have also cleared the opposition period, bringing its portfolio to more than 50 […]
Investor Brand Network
VERAXA Biotech (NASDAQ: VRXA) Shareholders Approve Corporate Governance, Financing Measures
VERAXA Biotech (NASDAQ: VRXA) announced that shareholders overwhelmingly approved all proposals presented at its Extraordinary General Meeting, with more than 99.94% of votes cast in favor and 72.20% of the company’s outstanding share capital represented. The approved measures include the introduction of conditional share capital for shareholder options and warrants, implementation of a capital band through Dec. 31, 2030 and […]
Investor Brand Network
VERAXA Biotech (NASDAQ: VRXA) Advances Bispecific ADC Program Under OmniAb Collaboration
VERAXA Biotech (NASDAQ: VRXA) announced the advancement of its bispecific antibody-drug conjugate (“bsADC”) program, VXA-222, after reaching a key technical milestone in its collaboration with OmniAb (NASDAQ: OABI). The company said OmniAb has successfully completed its discovery work, allowing the program to move into its next phase. VXA-222 is designed to target two tumor antigens with a single molecule using […]
Investor Brand Network
VERAXA Biotech AG (NASDAQ: VRXA) Appoints Christoph Erkel as Chief Scientific Officer
VERAXA Biotech (NASDAQ: VRXA) announced the appointment of Christoph Erkel, Ph.D., as chief scientific officer, effective immediately. Erkel, previously vice president of research and development, will lead advancement of the company’s proprietary BiTAC(R) platform technologies for the development of cancer therapies targeting solid tumors. He succeeds Rick Austin, Ph.D., who will depart following a transition period. […]
Investor Brand Network
VERAXA Biotech (NASDAQ: VRXA) Advances BiTAC(R)-TCE Development with Positive Regulatory Feedback from Germany
VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has taken another step in the development of its proprietary BiTAC(R)-TCE platform after receiving Scientific Advice from Germany’s Paul-Ehrlich-Institute (“PEI”), providing regulatory feedback on the biological rationale and proposed non-clinical development strategy for its lead therapeutic program. The announcement, released on July 20, […]
Investor Brand Network